[Articles] Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Di |2024-06-14T00:30:06+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

The RH5.1/Matrix-M vaccine candidate shows an acceptable safety and reactogenicity profile in both adults and 5–17-month-old children residing in a malaria-endemic area, with all children in the delayed third dose regimen reaching a level of GIA previo...

[Articles] Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

Di |2024-06-14T00:30:02+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for ...

[Comment] Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis

Di |2024-06-14T00:30:01+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

Yearly, about 410 000 patients worldwide develop rifampicin-resistant tuberculosis, resistant to the most powerful first-line tuberculosis drug. In 2012, treatment for rifampicin-resistant tuberculosis constituted mainly regimens of 18 months or longer...

[Correspondence] Survival analysis of patients with cholera admitted to treatment centres in Lusaka, Zambia

Di |2024-06-13T00:30:01+02:00Giugno 13th, 2024|Categorie: Coronavirus Lancet|

Cholera remains a global threat to health security, particularly in sub-Saharan Africa where outbreaks have become frequent, with increased magnitude and fatalities.1,2 While the world is preparing for the next pandemic, we explored clinical outcomes a...

[Correspondence] Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions

Di |2024-06-04T00:30:01+02:00Giugno 4th, 2024|Categorie: Coronavirus Lancet|

We have an ethical imperative to learn from recent influenza H1N1 and COVID-19 pandemics to better prepare for the next one. WHO has highlighted the need for surveillance frameworks that can be implemented across states.1 For any future epidemic or pan...

[Articles] Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies

Di |2024-06-01T00:30:01+02:00Giugno 1st, 2024|Categorie: Coronavirus Lancet|

VLA15 was safe, well tolerated, and elicited robust antibody responses to all six OspA serotypes. These findings support further clinical development of VLA15 using the 180 μg dose and 0-2-6-month schedule, which was associated with the greatest immune...

[Corrections] Correction to Lancet Infect Dis 2024; published online April 30. https://doi.org/10.1016/S1473-3099(24)00215-9

Di |2024-05-24T00:30:01+02:00Maggio 24th, 2024|Categorie: Coronavirus Lancet|

Ares-Gómez S, Mallah N, Santiago-Pérez M-I, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudina...

[Articles] Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design

Di |2024-05-24T00:30:01+02:00Maggio 24th, 2024|Categorie: Coronavirus Lancet|

Doxycycline PEP strongly reduced the incidence of chlamydia and syphilis in MSM, but we did not show efficacy of the 4CmenB vaccine for gonorrhoea. Doxycycline PEP should be assessed in other populations, such as heterosexual men and women, and its eff...

Torna in cima